By Gina Shaw
A multicenter, observational study that compared the effectiveness of ceftazidime-avibactam (CZA) with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) Pseudomonas aeruginosa infections shows no difference in overall clinical success, mortality, recurrent infections or resistance development between the two combinations, in data presented at IDWeek in Boston, on Oct. 13, 2023 (poster 1109).
The CACTUS study “was designed to answer what we think is an outstanding